Malignancies Clinical Trials in New York, New York
16 recruitingNew York, New York
Showing 1–16 of 16 trials
Recruiting
Phase 1Phase 2
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
B-cell Malignancies
AstraZeneca174 enrolled30 locationsNCT06542250
Recruiting
Phase 1Phase 2
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Hematologic Malignancies
Sellas Life Sciences Group160 enrolled25 locationsNCT04588922
Recruiting
Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled779 locationsNCT03486873
Recruiting
Phase 2
IVIG for Infection Prevention After CAR-T-Cell Therapy
Hematologic Malignancies
Fred Hutchinson Cancer Center150 enrolled7 locationsNCT05952804
Recruiting
Phase 1
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Solid TumorsHematologic Malignancies
Incyte Corporation280 enrolled22 locationsNCT07195916
Recruiting
Phase 2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Hematological Malignancies
Janssen Research & Development, LLC510 enrolled78 locationsNCT04634552
Recruiting
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Hematologic MalignanciesInherited Disorders of MetabolismInherited Abnormalities of Platelets+2 more
Center for International Blood and Marrow Transplant Research99,999 enrolled142 locationsNCT01351545
Recruiting
Phase 1Phase 2
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Hematological Malignancies
Daiichi Sankyo420 enrolled4 locationsNCT07220616
Recruiting
Phase 4
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
CholangiocarcinomaSolid Tumor MalignanciesGlioma+1 more
Rigel Pharmaceuticals16 enrolled2 locationsNCT07486713
Recruiting
Phase 1Phase 2
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Advanced Solid Malignancies
AstraZeneca695 enrolled33 locationsNCT05417594
Recruiting
Phase 1Phase 2
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Ovarian CancerMelanomaT-cell Lymphoma+1 more
BioInvent International AB176 enrolled25 locationsNCT04752826
Recruiting
Phase 2
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Hematologic Malignancies
Memorial Sloan Kettering Cancer Center40 enrolled7 locationsNCT07359859
Recruiting
Phase 2
A Study of Intensity-Modulated Pleural Radiation Therapy (IMPRINT) in People With Thymic Cancer That Has Spread to the Lining of the Lungs and Chest
Thymic MalignanciesPleural Metastases
Memorial Sloan Kettering Cancer Center36 enrolled7 locationsNCT05354570
Recruiting
Phase 3
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Solid TumorHematologic MalignancyAdvanced Malignancies
Novartis Pharmaceuticals50 enrolled15 locationsNCT06401356
Recruiting
Phase 1
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Myelodysplastic SyndromesRelapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AML+1 more
Institut de Recherches Internationales Servier291 enrolled30 locationsNCT02074839
Recruiting
Phase 1Phase 2
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
Hematological Malignancies
Smart Immune SAS36 enrolled1 locationNCT04959903